The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1 Royal Women's Hospital, Melbourne, VIC
- 2 Gynaecology Research Centre, Royal Women's Hospital, Melbourne, VIC
Correspondence: annabelle.brennan@thewomens.org.au
Competing interests:
No relevant disclosures.
- 1. Munro MG, Critchley HOD, Broder MS, et al. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011; 113: 3-13.
- 2. National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. Clinical guideline CG44. London: NICE; 2007. https://www.nice.org.uk/guidance/cg44/chapter/Recommendations#pharmaceutical-treatments-for-hmb (viewed June 2017).
- 3. The Society of Obstetricians and Gynaecologists of Canada. Abnormal uterine bleeding in pre-menopausal women. J Obstet Gynaecol Can 2013; 35(5): S1-S25.
- 4. Bitzer J, Heikinheimo O, Nelson AL, et al. Medical management of heavy menstrual bleeding: a comprehensive review of the literature. Obstet Gynecol Surv 2015; 70: 115-130.
- 5. Lethaby A, Duckitt K, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2013; (1): CD000400.
- 6. Department of Human Services. Medicare item reports. Canberra: Commonwealth of Australia; 2017. http://medicarestatistics.humanservices.gov.au/statistics/mbs_item.jsp (viewed June 2017).
- 7. Nelson A, Teal S. Medical therapies for chronic menorrhagia. Obstet Gynecol Surv 2007; 62: 272-281.
- 8. Matteson K, Rahn D, Wheeler T, et al. Nonsurgical management of heavy menstrual bleeding. Obstet Gynecol 2013; 121: 632-643.
- 9. Lethaby A, Hussain M, Rishworth JR, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2015; (4): CD002126.
- 10. Uhm S, Perriera L. Hormonal contraception as treatment for heavy menstrual bleeding. Clin Obstet Gynecol 2014; 57: 694-717.
- 11. Lethaby A, Irvine GA, Cameron IT. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008; (1): CD001016.
- 12. Irvine G, Campbell-Brown M, Lumsden M, et al. Randomised comparative trial of the intrauterine system and norethisterone levonorgestrel for treatment of idiopathic menorrhagia. BJOG 1998; 105: 592-598.
- 13. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2016; (1): CD003855.
- 14. Kaunitz A, Meredith S, Inki P, et al. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding. Obstet Gynecol 2009; 113: 1104-1116.
- 15. Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001; 357: 273-277.
- 16. Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188: 100-107.
- 17. Drayer SM, Catherino WH. Prevalence, morbidity, and current medical management of uterine leiomyomas. Int J Gynaecol Obstet 2015; 131: 117-122.
- 18. Ezzedine D, Norwitz E. Are women with uterine fibroids at increased risk for adverse pregnancy outcome? Clin Obstet Gynecol 2016; 59: 119-127.
- 19. Brohl AS, Li L, Andikyan V, et al. Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. Oncologist 2015; 20: 433-439.
- 20. Moravek M, Yin P, Ono M, et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum Reprod Update 2014; 21: 1-12.
- 21. Whitaker LHR, Williams ARW, Critchley HOD. Selective progesterone receptor modulators. Curr Opin Obstet Gynecol 2014; 26: 237-242.
- 22. Australian Government Department of Health, Therapeutic Goods Administration, Australian Public Assessment Reports for Prescription Medicines: Ulipristal acetate. Published 2 November 2016. https://www.tga.gov.au/auspar/auspar-ulipristal-acetate-0 (viewed June 2017).
- 23. Donnez J, Vázquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014; 101: 1565-1573.
- 24. Moroni RM, Vieira CS, Ferriani RA, et al. Pharmacological treatment of uterine fibroids. Ann Med Health Sci Res 2015; 4: 185-192.
- 25. Hornstein MD, Surrey ES, Weisberg GW, et al. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol 1998; 91: 16-24.
- 26. Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002; 99: 709.
- 27. Marret H, Fritel X, Ouldamer L, et al. Therapeutic management of uterine fibroid tumors: updated French guidelines. Eur J Obstet Gynecol Reprod Biol 2012; 165: 156-164.
- 28. The Society of Obstetricians and Gynaecologists of Canada. The management of uterine leiomyomas. J Obstet Gynaecol Can 2015; 37: 157-178.
- 29. Burke CT, Funaki BS, Ray CH Jr, et al. ACR Appropriatenes criteria on treatment of uterine leiomyomas. J Am Coll Radiol 2011; 8: 228-234.
- 30. Hehenkamp WJ, Volkers NA, Birnie E, et al. Symptomatic uterine fibroids: treatment with uterine artery embolization or hysterectomy — results from the randomized clinical Embolisation Versus Hysterectomy (EMMY) trial. Radiology 2008; 246: 823-832.
- 31. Kjerulff K, Rhodes J, Langenberg P, Harvey L. Patient satisfaction with results of hysterectomy. Am J Obstet Gynecol 2000; 183: 1440-1447.
- 32. Wise LA, Laughlin-Tommaso SK. Epidemiology of uterine fibroids: from menarche to menopause. Clin Obstet Gynecol 2016; 59: 1-24.
- 33. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin: alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol 2008; 112: 387-400.
- 34. Women’s Health Committee and Australasian CREI Consensus Expert Panel on Trial Evidence Group. Fibroids in infertility: consensus statement of the Australian and New Zealand College of Obstetricians and Gynaecologists and the ACCEPT Group. Sydney: RANZCOG; 2014. https://www.ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women's%20Health/Statement%20and%20guidelines/Clinical%20-%20Gynaecology/Fibroids-in-Infertility-(C-Gyn-27)-Review-November-2014.pdf?ext=.pdf (viewed June 2017).
- 35. The Society of Obstetricians and Gynaecologists of Canada. The management of uterine fibroids in women with otherwise unexplained infertility. J Obstet Gynaecol Can 2015; 37: 277-285.
- 36. Bosteels J, Kasius J, Weyers S, et al. Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities. Cochrane Database Syst Rev 2013; (1): CD009461.
- 37. Brady PA, Stanic AK, Styer AK. Uterine fibroids and subfertility: an update on the role of myomectomy. Curr Opin Obstet Gynecol 2013; 25: 255-259.
- 38. Lewis EI, Garguilo AR. The role of hysteroscopic and robot-assisted laparoscopic myomectomy in the setting of infertility. Clin Obstet Gynecol 2016; 59: 53-65.
- 39. Göçmen A, Şanlıkan F, Uçar MG. Comparison of robotic-assisted laparoscopic myomectomy outcomes with laparoscopic myomectomy. Arch Gynecol Obstet 2013; 287: 91-96.
- 40. Pundir J, Pundir V, Walavalkar R, et al. Robotic-assisted laparoscopic vs abdominal and laparoscopic myomectomy: systematic review and meta- analysis. J Minim Invasive Gynecol 2013; 20: 335-345.
- 41. Rossetti A, Sizzi O, Soranna L, et al. Long-term results of laparoscopic myomectomy: recurrence rate in comparison with abdominal myomectomy. Hum Reprod 2001: 16: 770-774.
- 42. Jin C, Hu Y, Chen X, et al. Laparoscopic versus open myomectomy – a meta-analysis if randomized controlled trials. Eur J Obstet Gynecol Reprod Biol 2009; 145: 14-21.
- 43. Bhave Chittawar P, Franik S, Pouwer AW, Farquhar C. Minimally invasive surgical techniques versus open myomectomy for uterine fibroids. Cochrane Database Syst Rev 2014; (10): CD004638.
- 44. Chittawar PB, Kamath MS. Review of nonsurgical/minimally invasive treatments and open myomectomy for uterine fibroids. Curr Opin Obstet Gynecol 2015; 27: 391-397.
- 45. Gupta JK, Sinha A, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. C Cochrane Database Syst Rev 2014; (12): CD005073.
- 46. Silberzweig JE, Powell DK, Matsumoto AH, Spies JB. Management of uterine fibroids: a focus on uterine-sparing interventional techniques. Radiology 2016; 280: 675-692.
- 47. Royal College of Obstetricians and Gynaecologists and the Royal College of Radiologists. Clinical recommendations on the use of uterine artery embolisation (UAE) in the management of fibroids, 3rd ed. London: RCOG and RCR; 2013. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/uterine-artery-embolisation-in-the-management-of-fibroids (viewed June 2017).
- 48. Women’s Health Committee, Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Uterine artery embolisation for the treatment of uterine fibroids. Sydney: RANZCOG: 2014. https://www.ranzcog.edu.au/RANZCOG_SITE/media/RANZCOG-MEDIA/Women's%20Health/Statement%20and%20guidelines/Clinical%20-%20Gynaecology/Uterine-Artery-Embolisation-(C-Gyn-23)-Review-November-2014.pdf?ext=.pdf (viewed June 2017).
- 49. Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update 2016; 22: 665-686.
- 50. Hickey M, Hammond I. What is the place of uterine artery embolisation in the management of symptomatic uterine fibroids. Aust N Z J Obstet Gynaecol 2008; 48: 360-368.
- 51. Czuczwar P, Stępniak A, Wrona W, et al. The influence of uterine artery embolisation on ovarian reserve, fertility, and pregnancy outcomes – a review of literature. Menopause Rev 2016; 15: 205-209.
- 52. Spies JB, Myers ER, Worthington-Kirsch R, et al. FIBROID Registry Investigators. The FIBROID Registry: symptom and quality-of-life status 1 year after therapy. Obstet Gynecol 2005; 106: 1309-1318.
- 53. Dutton S, Hirst A, McPherson K, et al. A UK multicentre retrospective cohort study comparing hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids (HOPEFUL study): main results on medium-term safety and efficacy. BJOG 2007; 114: 1340-1351.
- 54. Clark NA, Mumford SL, Segars JH. Reproductive impact of MRI-guided focused ultrasound surgery for fibroids: a systematic review of the evidence. Curr Opin Obstet Gynecol 2014; 26: 151-161.
- 55. Fennessy FM, Tempany CM. A review of magnetic resonance imaging guided focused ultrasound surgery of uterine fibroids. Top Magn Reson Imaging 2006; 17: 173-179.
- 56. Hesley GK, Gorny KR, Henrichson TL, et al. A clinical review of focused ultrasound ablation with magnetic resonance: an option for treating uterine fibroids. Ultrasound Q 2008; 24: 131-139.
- 57. Hindley J, Gedroyc WM, Regan L, et al. MRI guidance of focused ultrasound therapy of uterine fibroids: early results. AJR Am J Roentgenol 2004; 183: 1713-1719.
- 58. Lethaby A, Hickey M, Garry R, et al. Endometrial resection/ablation techniques for heavy menstrual bleeding. Cochrane Database Syst Rev 2009; (4):CD001501.
- 59. Al-Hendy A, Salama S. Gene therapy and uterine leiomyoma: a review. Hum Reprod Update 2006; 12: 385-400.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
Summary